Vizsgálati helyszín
Eastern Health
Box Hill, Victoria 3128, AusztráliaMég nincs intézményhez kötve
- 17futó vizsgálat
- 3lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 20 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 2. fázis6 vizsgálat
- 3. fázis6 vizsgálat
- Korai 1. fázis1 vizsgálat
- 1. fázis1 vizsgálat
- 2/3. fázis1 vizsgálat
- 4. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz11 vizsgálat
- Toboroz5 vizsgálat
- Lezárult3 vizsgálat
- Még nem toboroz1 vizsgálat
- Fő szponzor
- Regeneron Pharmaceuticals3 vizsgálat
- Australasian Gastro-Intestinal Trials Group2 vizsgálat
- Olivia Newton-John Cancer Research Institute2 vizsgálat
- Austin Health1 vizsgálat
- Cassava Sciences, Inc.1 vizsgálat
- és még 11
Futó vizsgálatok
Még nem toboroz
Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)
NCT07527819· Peter MacCallum Cancer Centre, Australia· Forrás
Contact: Dr Iris Tung
Toboroz
Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study
NCT07055542· University of Melbourne· Forrás
Contact: Frank Thien, MD PhD
Toboroz
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
NCT06963827· 3. fázis· Takeda· Forrás
Contact: Darren Lee (principal investigator)
Toboroz
Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis
NCT06850727· 2. fázis· Odyssey Therapeutics, Inc.· Forrás
Contact: Study Coordinator
Toboroz
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
NCT06697301· 2/3. fázis· Eikon Therapeutics· Forrás
Contact: LaiWan Reid
Toboroz
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
NCT06284317· 3. fázis· ETOP IBCSG Partners Foundation· Forrás
Contact: Phillip Parente
Fut, nem toboroz
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
NCT06190951· 2. fázis· Regeneron Pharmaceuticals· Forrás
Fut, nem toboroz
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
NCT06161441· 2. fázis· Regeneron Pharmaceuticals· Forrás
Fut, nem toboroz
Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.
NCT05788081· 2. fázis· Olivia Newton-John Cancer Research Institute· Forrás
Fut, nem toboroz
Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease
NCT05701358· Population Health Research Institute· Forrás
Fut, nem toboroz
Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer
NCT05694936· 2. fázis· Australasian Gastro-Intestinal Trials Group· Forrás
Fut, nem toboroz
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
NCT05608291· 3. fázis· Regeneron Pharmaceuticals· Forrás
Fut, nem toboroz
RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer
NCT05862051· Australasian Gastro-Intestinal Trials Group· Forrás
Fut, nem toboroz
Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy
NCT04962126· 2. fázis· Olivia Newton-John Cancer Research Institute· Forrás
Fut, nem toboroz
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
NCT04680052· 3. fázis· Incyte Corporation· Forrás
Fut, nem toboroz
Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A
NCT03245021· 1. fázis· Dr. Eliza Hawkes· Forrás
Fut, nem toboroz
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
NCT03229200· 4. fázis· Pharmacyclics Switzerland GmbH· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek